MedTrace Logo

A Study to Evaluate the Efficacy of Cemsidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma

NCT07284758 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2026-03-12

No results posted yet for this study

Summary

This is a Phase 2, open-label, single-arm, multicenter study to assess the antimyeloma activity and further characterize the safety, tolerability, PK, and PD of cemsidomide in combination with dexamethasone in participants with relapsed/refractory multiple myeloma (r/r MM).

Conditions

Interventions

DRUG

Cemsidomide

dosed orally (PO) once a day (QD) 14 days on/14 days off for each 28-day cycle

DRUG

Dexamethasone

dosed PO once a week (QW) on Days 1, 8, 15, and 22 for each 28-day cycle

Sponsors & Collaborators

  • C4 Therapeutics, Inc.

    lead INDUSTRY

Principal Investigators

  • Binod Dhakal, M.D. · Medical College of Wisconsin

  • Martin Kaiser, M.D. · The Royal Marsden

  • Aurore Perrot, M.D. · Universite de Toulouse

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-02-18
Primary Completion
2030-03-31
Completion
2030-03-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07284758 on ClinicalTrials.gov